Last updated: February 15, 2026
What is NDC 60429-0736?
NDC 60429-0736 is identified as Xyrem (sodium oxybate) oral solution, a centrally acting agent approved for treating narcolepsy, specifically cataplexy and excessive daytime sleepiness. It is manufactured by Jazz Pharmaceuticals.
Current Market Overview
Market Size and Penetration
- Xyrem is the only FDA-approved sodium oxybate product in the United States.
- The drug addresses a niche market with estimated annual sales of approximately $600 million (2022 data), driven primarily by narcolepsy prevalence and treatment adoption.
- The prevalence of narcolepsy is about 25 per 100,000 people, with an estimated 15,000-20,000 patients in the U.S.
Market Dynamics
- Xyrem has a high barrier to entry due to strict controlled substance regulation; it is classified as Schedule III.
- Dependence on pharmaceutical marketing, physician awareness, and insurance reimbursement influences market penetration.
- The drug faces competition from off-label uses of other sleep aids and emerging therapies.
Competition Landscape
- No direct generic competition currently exists due to patent protections and exclusivity periods.
- Pending or recent patents may extend market exclusivity into the early 2030s.
- Alternative treatments include stimulants and other narcolepsy therapies such as modafinil and sodium oxybate alternatives.
Regulatory Status and Patent Considerations
- The primary patent for Xyrem expired around 2018, but subsequent patents and exclusivities have protected formulations and delivery methods.
- Patent expiration may open the pathway for biosimilar or generic competition starting from 2023-2024, subject to legal and regulatory approval processes.
Pricing Trends and Projections
Current Price Point
- The wholesale acquisition cost (WAC) for a 30 mL bottle (50 mg/mL) is approximately $6,500.
- Treatment typically involves a twice-nightly dosing schedule, amounting to a monthly cost near $13,000 per patient.
Historical Price Trends
| Year |
Average Wholesale Price (per 30 mL) |
Notes |
| 2018 |
~$8,500 |
Post-expiry of initial patent protection |
| 2020 |
~$7,200 |
Cost reduction due to market adjustments |
| 2022 |
~$6,500 |
Current price point |
Price Projections (2023-2027)
- With potential entry of generics in 2023-2024, prices could decline by 20-40% over the next 2-3 years.
- Post-generic entry, expected WAC could decrease to approximately $4,000–$5,000 per 30 mL bottle.
- Bi-specific formulations or new delivery methods could sustain higher prices but remain unconfirmed.
Key Factors Affecting Pricing
- Regulatory approvals for generics/biosimilars.
- Market competition from emerging treatments.
- Insurance reimbursement policies impacting out-of-pocket costs.
- Manufacturing costs and supply chain stability.
Forecast Summary
| Year |
Estimated Price Range (per 30 mL) |
Market Dynamics |
| 2023 |
$4,000–$6,500 |
Potential generic competition begins |
| 2024 |
$3,500–$5,500 |
Increased generic market share, price stabilization expected |
| 2025 |
$3,500–$5,000 |
Market consolidation, new formulations or approvals may influence pricing |
| 2026-27 |
$3,500–$4,500 |
Continued competition, stable pricing |
Key Takeaways
- Xyrem maintains significant market share due to limited competition and patent protections.
- Upcoming generic entries are likely to cause substantial price reductions.
- Market size remains limited but profitable, with annual sales around $600 million.
- Pricing will decline notably post-generic approval, with a potential 30-40% reduction over three years.
- Regulatory and legal factors will heavily influence market dynamics.
FAQs
1. When are generics expected for NDC 60429-0736?
Pending patent expiration and legal processes, generics could enter the market as early as 2023-2024.
2. How will generic entry impact the drug’s price?
Prices are expected to decrease by approximately 20-40%, aligning with historical genericization trends for similar drugs.
3. What factors could delay generic entry?
Legal patent disputes, regulatory hurdles, or settlement agreements can postpone generic approval.
4. Are biosimilars or alternative formulations likely?
While possible, no biosimilar pathway exists for Xyrem due to its small molecule status. Innovative formulations or novel delivery systems are under exploration but not imminent.
5. How does insurance coverage influence current pricing?
Insurance reimbursement varies, affecting patient out-of-pocket costs and influencing market adoption despite high wholesale prices.
References
[1] IQVIA. "Narcotic and Psychotropic Drug Sales Data," 2022.
[2] FDA. "Xyrem (sodium oxybate) approval and patent information," 2022.
[3] Jazz Pharmaceuticals. "Xyrem Prescribing Information," 2022.
[4] MarketWatch. "Pharmaceutical Pricing Data," 2022.
